Binds Antigens Of Multiple Bacterial Species (e.g., Multivalent Antiserum That Binds Antigens Of Multiple Bacterial Species, Etc.) Patents (Class 424/163.1)
-
Patent number: 8916162Abstract: Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.Type: GrantFiled: February 18, 2011Date of Patent: December 23, 2014Inventor: Alexey Gennadievich Zdanovsky
-
Patent number: 8541006Abstract: The present invention provides methods and kits for biofilm detection.Type: GrantFiled: July 30, 2008Date of Patent: September 24, 2013Assignees: University of Maryland, Baltimore, The Arizona Board of Regents, a body corporate acting for and on behalf of Northern Arizona UniversityInventors: Jeffrey G. Leid, Timothy L. Vail, Jennifer M. Kofonow, Mark E. Shirtliff, Rebecca A. Brady
-
Patent number: 8361441Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided.Type: GrantFiled: September 29, 2009Date of Patent: January 29, 2013Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yung-Luen Shih, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Patent number: 8263078Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: GrantFiled: September 5, 2008Date of Patent: September 11, 2012Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
-
Patent number: 8137679Abstract: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as Lactobacillus spp. infect fermentation systems, they will further reduce alcohol conversion efficiency. Colony forming immunogens such as Lactobacillus spp.Type: GrantFiled: January 12, 2009Date of Patent: March 20, 2012Assignee: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness
-
Publication number: 20120027771Abstract: The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided.Type: ApplicationFiled: April 12, 2011Publication date: February 2, 2012Inventor: THOMAS L. CANTOR
-
Patent number: 8101367Abstract: Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.Type: GrantFiled: November 24, 2009Date of Patent: January 24, 2012Assignee: Medical Diagnostic Laboratories, LLCInventors: Tera L. McCool, Chien Chang Loa, Eli Mordechai, Martin E. Adelson
-
Patent number: 8071102Abstract: Novel vaccines include polypeptides that comprise regions corresponding to a chemokine and a hapten. The hapten can be an amino acid sequence corresponding to the Meningitis Related Homologous Antigenic Sequences (MRHAS) of bacterial and viral agents known to cause meningitis. Protective immunity in a host susceptible to meningitis can be induced by inoculating the host with immunogenic amount of such a vaccine.Type: GrantFiled: January 24, 2000Date of Patent: December 6, 2011Inventors: Diane Van Alstyne, Lawrence R. Sharma
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 7919258Abstract: Methods for diagnosing Mycobacterium tuberculosis infection in a human that include providing blood serum, contacting the serum with an Eis antigen fixed on a substrate, thereby forming complexes of Eis antigen with a human antibody that binds to the Eis antigen, contacting the antibody/Eis complexes with a labeled anti-human secondary antibody, and measuring a titer of the human antibody bound to the Eis antigen. In addition, statistically significant positive or negative diagnosis of infection with Mycobacterium tuberculosis is provided by comparing patient serum antibody titer with a second titer from a negative control blood sample.Type: GrantFiled: October 10, 2006Date of Patent: April 5, 2011Assignee: Arizona Board of Regents on behalf of the University of ArizonaInventors: Richard L. Friedman, Linoj P. Samuel
-
Patent number: 7851166Abstract: A method of detecting a surrogate marker for active tuberculosis involves obtaining first, second and third samples from a subject suspected of having active tuberculosis, diluting the first sample and exposing part of it to an immobilized mycolic acid antigen in a test vessel and part of it to an immobilized mycolic antigen in a control vessel. The second sample is exposed to mycolic acid antigen-containing liposomes and the third sample is exposed to liposomes not containing mycolic acid antigens. The second sample is added to the test vessel and the third to the control vessel and binding of antibodies to the mycolic acid and antigen in both the test and control vessel is detected. The degree of binding between the test and control vessels is compared and lesser binding in the test vessel is an indicator of the presence of antibodies to the mycolic acid antigen.Type: GrantFiled: May 11, 2005Date of Patent: December 14, 2010Assignee: The University of PretoriaInventors: Jan Adrianus Verschoor, Dismore Gilbert Ramathudi Siko, Sandra Van Wyngaardt
-
Patent number: 7807139Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.Type: GrantFiled: January 23, 2009Date of Patent: October 5, 2010Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Publication number: 20100150942Abstract: The present invention describes a method for treating, removing or preventing a bacterial infection, which method comprises administering to a human suffering, suspected of suffering or at risk of suffering from Staphylococcus aureus (S. aureus) infection, a Streptococcus infection, Escherichia coli (E. coli) infection, Pseudomonas aeruginosa (P. aeruginosa) infection, Acinetobacter baumannii (A. baumannii) infection, Enterococcus faecium (E. faecium) infection and/or Clostridium difficile (C. difficile) infection, an effective amount of human polyclonal antibodies affinity purified from a human blood sample with an antigenic preparation comprising cellular and/or secreted antigen(s) from bacterial cells selected from S. aureus, a Streptococcus, E. coli, P. aeruginosa, A. baumannii, E. faecium, C. difficile or a combination thereof, and optionally, wherein said affinity purified human polyclonal antibodies are purified (e.g.Type: ApplicationFiled: December 1, 2009Publication date: June 17, 2010Inventor: Thomas L. CANTOR
-
Patent number: 7727711Abstract: Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.Type: GrantFiled: March 7, 2008Date of Patent: June 1, 2010Assignee: Medical Diagnostic Laboratories, LLCInventors: Tera L. McCool, Chien Chang Loa, Eli Mordechai, Martin E. Adelson
-
Patent number: 7608247Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided is an antibody binding to OmpA that can assay OmpA levels in a biological sample and detect or diagnose bacterial infection in central nervous system and/or peripheral blood circulation.Type: GrantFiled: March 11, 2008Date of Patent: October 27, 2009Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, I-Jen Huang, Neng-Yao Shih, Ko-Jiunn Liu, Mei-Ru Chen, Wen-Shyang Hsieh, Chi-Hsin Lee
-
Patent number: 7604953Abstract: A process of detection of the causative agent of Johne's disease (Mycobacterium avium subsp. paratuberculosis) (MAP) by detecting shedding of surface protein of MAP. A preferred way is use of surface enhanced Raman Spectroscopy. The system of detecting MAP shedding of protein provides early detection and diagnosis, and therefore allows early treatment for Johne's disease in ruminant animals.Type: GrantFiled: May 30, 2008Date of Patent: October 20, 2009Assignees: Iowa State University Research Foundation, Inc., The United States of America as represented by the Department of Agriculture/Cooperative State Research Education and Extension Service (USDA/CSREES)Inventors: Marc D. Porter, Betsy Jean Yakes, Robert J. Lipert, John P. Bannantine
-
Patent number: 7531163Abstract: The present invention provides novel enrichment, testing and detection methods for detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical, environmental samples and other types of samples analyzed by enrichment-detection methods. In preferred aspects, a sample is obtained at a first location and is diluted (e.g., in the case of a solid or semi-solid sample or liquid) at the first location at a ratio of about 1:0 (wt./vol.) to 1:2 (wt./vol.), or greater, preferably at a ratio of about 1:0.1 (wt./vol.) or greater, or more preferably, at a ratio of about 1:2 (wt./vol.) or greater. The diluted sample is incubated at an optimal temperature in an incubator and either tested locally, or sent in a shipping incubator to a second location that is a remote test location. The incubated sample is received and tested at the second location by assaying the sample, or a portion thereof, with an assay suitable to detect the pathogen or other microbe.Type: GrantFiled: May 17, 2004Date of Patent: May 12, 2009Assignee: Institute for Environmental Health, Inc.Inventor: Mansour Samadpour
-
Patent number: 7235644Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: March 15, 2006Date of Patent: June 26, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 7195763Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.Type: GrantFiled: August 5, 2004Date of Patent: March 27, 2007Assignee: The Texas A & M Univerisity SystemInventors: Yi Xu, Magnus A. O. Hook
-
Patent number: 7025963Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: June 6, 1995Date of Patent: April 11, 2006Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 6994854Abstract: The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis, B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the invention is antibodies, especially monoclonal antibodies, directed against these epitopes.Type: GrantFiled: July 19, 2001Date of Patent: February 7, 2006Assignee: Institut PasteurInventors: Fotini Betsou, Peter Sebo, Nicole Gutso
-
Patent number: 6936247Abstract: The present invention relates to isolated parasitic helminth nucleic acid sequences capable of hybridizing, under stringent conditions, to at least a portion of D. immitis nucleic acid sequence p4 and/or to at least a portion of D. immitis nucleic acid sequence p22U; to isolated parasitic helminth proteins that are encoded by such parasitic helminth nucleic acid sequences and that are capable of selectively binding to at least one component of immune serum capable of inhibiting helminth development; and to antibodies raised against such isolated parasitic helminth proteins. The present invention also relates to therapeutic compositions comprising such isolated nucleic acid sequences, proteins and/or antibodies. The present invention also includes methods to produce and use such nucleic acids, proteins, antibodies and therapeutic compositions capable of protecting animals from parasitic helminth infection and, particularly, from heartworm, infection.Type: GrantFiled: November 19, 1998Date of Patent: August 30, 2005Assignees: Heska Corporation, Colorado State University Research FoundationInventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
-
Patent number: 6887481Abstract: The present invention relates generally to molecules derived from a Mycobacterium species and recombinant, synthetic, derivative, homologue and analogue forms of said molecules. The molecules of the present invention are useful in diagnostic assays for Mycobacterium in biological and environmental samples. The present invention is particularly directed to molecules derived from Mycobacterium tuberculosis and related organisms and even more particularly to recombinant forms of these molecules or synthetic, derivative, homologue or analogue forms thereof and their use in diagnostic and therapeutic protocols for tuberculosis or other disease conditions associated with M. tuberculosis or related organisms.Type: GrantFiled: December 15, 1999Date of Patent: May 3, 2005Assignee: Agency for Science, Technology and ResearchInventors: Lily Chan, Maxey Ching Ming Chung, Renee Lay Hong Lim
-
Patent number: 6881410Abstract: The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralising agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal holomogues of IstA and IstB and immunogenic fragments thereof, and their uses in methods of treatment and diagnosis of the human or animal body.Type: GrantFiled: January 25, 2002Date of Patent: April 19, 2005Assignee: Neu Tec Pharma PLCInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 6803035Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.Type: GrantFiled: January 22, 2002Date of Patent: October 12, 2004Assignee: Arkion Life SciencesInventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
-
Patent number: 6790661Abstract: The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mammal. The method comprises contacting a sample of the donor blood or a blood product with a set of binding agents that comprises binding agents that specifically bind to Gram-negative bacterial antigen and/or binding agents that specifically bind to Gram-positive bacterial antigen, and determining binding of the set of binding agents to the sample, wherein binding indicates the presence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product and no binding indicates the absence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product.Type: GrantFiled: July 14, 2000Date of Patent: September 14, 2004Assignee: Verax Biomedical, Inc.Inventor: Timothy T. Goodnow
-
Publication number: 20040132178Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: September 2, 2003Publication date: July 8, 2004Inventors: Deborah Haines, Gordon Allan, John Ellis, Brian Meehan, Edward Clark, Lori Hassard, John Harding, Catherine Elisabeth Charreyre, Gilles Emile Chappuis, Francis McNeilly, Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
-
Publication number: 20040109851Abstract: This invention provides methods for silencing a pre-existing immune response in a mammal, as for example, in the setting of autoimmune diseases. The method comprises administering to a mammal immature dendritic cells which have been contacted in vitro with an antigen, or to target the antigen to immature dendritic cells in vivo, in order to silence and/or suppress a pre-existing CD8+T cell immune response and induce IL-10 producing CD8+T cells in said mammal. This invention further relates to methods for propagating immature dendritic cells, for maintaining immaturity by modification ex vivo, and uses thereof, including generation of regulatory T cells for passive immunotherapy. The present invention also relates to compositions and kits comprising immature dendritic cells and antigens.Type: ApplicationFiled: December 23, 2003Publication date: June 10, 2004Inventors: Madhav V. Dhodapkar, RalphM M Stein, Nina Bhardwaj
-
Patent number: 6743430Abstract: Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.Type: GrantFiled: March 29, 1995Date of Patent: June 1, 2004Inventors: Richard E. Parizek, Lonny E. Vlieger, Sharon A. Bryant, Stuart K. Nibbelink, Michael J. McGinley
-
Patent number: 6733983Abstract: The invention relates to a method for identifying a Mycobacterium species comprising the steps of: a) contacting at least one immuno-cross reactive antigen component of a mycobacterial species with a sample of a body fluid of a human or animal individual; b) contacting at least one antibody, which is capable of reacting with a mycobacterial antigen, with said body fluid sample; c) detecting the presence of antigen-antibody complexes, and identifying the Mycobacterium species present in said body fluid sample.Type: GrantFiled: July 7, 2000Date of Patent: May 11, 2004Assignee: Kreatech Biotechnology, B.V.Inventors: Hendrik-Jan Houthoff, Saskia Kroon-Swart, Remco Van Der Meulen, Soenita Goerdayal, Arend Kolk, Lenka Perira Arias-Bouda, Sjoukje Kuyper
-
Patent number: 6713059Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.Type: GrantFiled: April 11, 2002Date of Patent: March 30, 2004Assignee: University of RochesterInventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson
-
Patent number: 6623737Abstract: The invention is related to antibodies, particularly monoclonal antibodies, which recognize particularly epitopes of the intimin protein of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of detecting such E. coli by use of these antibodies, and kits containing these antibodies for diagnosis.Type: GrantFiled: April 2, 1998Date of Patent: September 23, 2003Assignee: Imperial College of Science, Technology & MedicineInventors: Gordon Dougan, Gad Frankel
-
Patent number: 6582925Abstract: The use of genetic methodology based on the fusion of the proteins with the alcaline phosphatase (Lim et al., 1995) has allowed the isolation of a new exported protein of M. tuberculosis. In the present article, first of all the isolation of a gene encoding this exported protein called DES is described as well as its characterization and its distribution among the different mycobacterial species. It is notably shown that the protein has in its primary sequence amino acids only found at the level of active sites of enzymes of class II diiron-oxo proteins family. Among the proteins of this family, DES protein of M. tuberculosis does not present significative homologies with stearoyl ACP desaturases. Secondly, the antigenic feature of this protein has been studied. For this, DES protein of M. tuberculosis has been overexpressed in E. coli under recombinant and purified protein form from this bacterium. The reactivity of tuberculous patients sera infected by M. tuberculosis or M.Type: GrantFiled: April 20, 1999Date of Patent: June 24, 2003Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 6544516Abstract: The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralizing agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal homologues of IstA and IstB and immunogenic fragment thereof, and their uses in methods of treatment and diagnosis of the human or animal body.Type: GrantFiled: January 4, 1999Date of Patent: April 8, 2003Assignee: NeuTec Pharma plcInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 6495334Abstract: A truncated SE fimbria antigen useful as an antigen for immunoassay diagnosis of Salmonella enteritidis (SE) infection or evidence of infection.Type: GrantFiled: May 20, 1999Date of Patent: December 17, 2002Assignee: Regents of the University of MinnesotaInventors: Gireesh Rajashekara, Kakambi V. Nagaraja, Vivek Kapur
-
Patent number: 6416962Abstract: The invention relates to a method for identifying a Mycobacterium species responsible for a mycobacterial infection in human or animal, comprising selecting a suitable mycobacterial species and strain; preparing at least one mycobacterial antigen, respectively antigen preparation; binding the antigen, respectively the antigen preparation to a suitable carrier; causing the binding antigen to react with antibodies from serum of an individual infected with a Mycobacterium species; making visible antigen-antibody reactions for a suitable antibody (sub-)class; and identifying the responsible Mycobacterium species on the basis of the reactions which are made visible. The invention further provides a diagnostic kit which takes the form of a dip-stick on which is arranged a carrier strip with mycobacterial antigens binding thereto, and means for visualizing antigen-antibody reactions occurring on the carrier after contact with the serum for testing.Type: GrantFiled: October 5, 1998Date of Patent: July 9, 2002Assignee: Kreatech Biotechnology B.V.Inventors: Pranab Khumar Das, Remco Maria Van Es, Hendrik Jan Houthoff
-
Patent number: 6383763Abstract: The present invention is directed to methods and compositions for the detection of infection and disease due to members of the genus Mycobacterium. In particular, the present invention is well-suited to the detection and identification of patients with disease or infection due to M. tuberculosis or MAC.Type: GrantFiled: July 26, 1996Date of Patent: May 7, 2002Assignee: Case Western Reserve UniversityInventor: Robert S. Wallis
-
Patent number: 6376203Abstract: Mouse is immunized with an antigen of a lipid fraction originating from Mycoplasma fermentans. Its spleen cells are fused with mouse myeloma cells to prepare hybridomas. A hybridoma is selected, which produces a monoclonal antibody having reaction specificity to GGPL-III that is a phosphocholine-containing glycoglycerolipid specific to Mycoplasma fermentans. Mycoplasma fermentans is detected by using the obtained antibody.Type: GrantFiled: July 8, 1999Date of Patent: April 23, 2002Assignee: Seikagaku CorporationInventors: Kazuhiro Matsuda, Naoki Yamamoto
-
Patent number: 6365156Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: GrantFiled: April 14, 2000Date of Patent: April 2, 2002Assignee: Osel, Inc.Inventor: Peter P. Lee
-
Patent number: 6350449Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 1999Date of Patent: February 26, 2002Assignee: Baxter International Inc.Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6258359Abstract: There is provided an immunogenic composition capable of inducing protective antibodies against Helicobacter infection characterized in that it comprises: i) at least one sub-unit of a urease structural polypeptide from Helicobacter pylori (SEQ ID NO: 22,26), or a fragment thereof, said fragment being recognized by antibodies reacting with Helicobacter felis urease (SEQ ID NO: 20-21), and/or at least one sub-unit of a urease structural polypeptide from Helicobacter felis (SEQ ID NO: 20-21), or a fragment thereof, said fragment being recognized by antibodies reacting with Helicobacter pylori urease (SEQ ID NO: 22-26); ii) and/or, a heat shock protein (Hsp), or chaperonin, from Helicobacter, or a fragment of said protein. The preparation, by recombinant means, of such immunogenic compositions is also provided.Type: GrantFiled: June 6, 1995Date of Patent: July 10, 2001Assignee: Institut PasteurInventors: Agnes Labigne, Sebastian Suerbaum, Richard L. Ferrero, Jean-Michel Thiberge